# Formula M-51: Advanced Exercise Mimetic Peptide Blend

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Overview

**Formula Classification:** Dual-pathway metabolic modulator & exercise mimetic – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**
- 5-Amino-1MQ – 50 mg
- SLU-PP-332 – 1 mg

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to ensure optimal absorption and bioavailability.

**Therapeutic Intent:**
- To replicate the metabolic and body composition benefits of physical exercise by simultaneously inhibiting fat storage (5-Amino-1MQ) and increasing fat oxidation in muscle (SLU-PP-332). This formula is designed for individuals seeking to improve body composition, enhance metabolic rate, and achieve the physiological benefits of exercise, particularly those who may be unable to engage in intense physical activity.

---

## 2. Detailed Mechanism of Action

Formula M-51 integrates two powerful, synergistic metabolic modulators to reprogram cellular energy handling.

### 2.1 5-Amino-1MQ: NNMT Inhibition & Adipose Reprogramming

5-Amino-1MQ is a potent inhibitor of Nicotinamide N-Methyltransferase (NNMT), an enzyme highly expressed in fat tissue. By inhibiting NNMT, it increases intracellular NAD+ levels and alters adipocyte metabolism, reducing fat storage and promoting energy expenditure [1].

### 2.2 SLU-PP-332: Pharmacological Exercise Mimicry

SLU-PP-332 is a pan-agonist of the Estrogen-Related Receptors (ERRs), which act as master regulators of cellular energy metabolism. It induces a gene expression profile in muscle that mimics endurance exercise, leading to increased fatty acid oxidation, mitochondrial biogenesis, and resting energy expenditure [2].

---

## 3. Synergistic Integration Table

| Level | Primary Pathway | Key Components | Integrated Clinical Effect |
|---|---|---|---|
| Adipose Tissue | NNMT Inhibition & NAD+ Salvage | 5-Amino-1MQ | Blocks fat storage, increases cellular energy, and promotes a "browning" of white adipose tissue. |
| Muscle Tissue | ERR Agonism & Fuel Oxidation | SLU-PP-332 | Increases the muscle's capacity to burn fat for energy, mimicking the effects of endurance training. |
| Systemic | Body Composition & Metabolism | Both | A powerful "push-pull" effect: fat is pushed out of storage and muscle is pulled to burn it, leading to significant fat loss and improved metabolic health. |

---

## 4. Key Clinical Benefits

| Domain | Key Benefits |
|---|---|
| Body Composition | Significant reduction in body weight and fat mass; preservation of lean muscle mass. |
| Metabolic Health | Improved insulin sensitivity, lower cholesterol and triglycerides, and enhanced glucose tolerance. |
| Energy & Performance | Increased resting energy expenditure and potential for enhanced physical endurance. |
| Cellular Health | Increased NAD+ levels and mitochondrial biogenesis, supporting cellular longevity and resilience. |

---

## 5. Patient Expectations & Timeline

| Timeframe | Expected Changes |
|---|---|
| 1-2 Weeks | Initial increase in energy levels and potential for mild thermogenic effect. |
| 2-4 Weeks | Noticeable changes in body composition, with a reduction in fat mass and improved muscle definition. |
| 1-3 Months | Significant weight loss and improvements in metabolic markers (lipids, glucose). |
| 3-6+ Months | Achievement of body composition goals and long-term maintenance of a healthier metabolic profile. |

---

## 6. Dosing & Administration

- **Standard Dose:** One capsule daily.
- **Timing:** Can be taken with or without food. Morning administration is often preferred.
- **Optimization:** Combine with a healthy diet and regular exercise to maximize results.

---

## 7. Safety Profile

- **Overall:** Both are novel compounds with favorable preclinical safety profiles. Long-term human data is not yet available.
- **Absolute Contraindications:** Pregnancy and lactation; known hypersensitivity.
- **Tolerability:** Generally well-tolerated in preclinical studies with no significant adverse effects reported.

---

## 8. Drug Interaction Considerations

| Drug/Class | Interaction / Management |
|---|---|
| N/A | No significant drug interactions have been identified in preclinical studies. However, caution is advised until human data is available. |

---

## 9. References

[1] Neelakantan, H., et al. (2019). The small molecule NNMT inhibitor, 5-amino-1MQ, reverses diet-induced obesity, insulin resistance and fatty liver disease. *Biochemical Pharmacology*, 167, 103-113.

[2] Billon, C., et al. (2024). A pan-ERR agonist induces a thermogenic-like exercise-mimetic response in muscle. *Journal of Pharmacology and Experimental Therapeutics*, 388(2), 232-240.
